# Methemoglobinemia

Confirm suspected methemoglobinemia with blood-gas co-oximetry when cyanosis or low pulse oximetry is disproportionate to cardiopulmonary findings, immediately remove oxidant exposure, and use symptom-, concentration-, and oxygen-delivery risk–based antidotal treatment while avoiding methylene blue in G6PD deficiency.

**Clinical question:** How should physicians confirm, risk-stratify, treat, and monitor suspected acquired or hereditary methemoglobinemia?

Updated: 2026-09-16T00:07:11.915416+00:00

## What matters in practice
- Order arterial or venous blood-gas co-oximetry—not pulse oximetry alone—to confirm and quantify methemoglobin in unexplained cyanosis or hypoxemia that does not correct as expected with oxygen. [7][12][23]
- Acute onset after an oxidant exposure favors acquired disease; lifelong cyanosis, affected relatives, blue sclera, or consanguinity should trigger evaluation for CYB5R3 deficiency or HbM disease. [18][21][24]
- For acquired methemoglobinemia, treat symptomatic patients at a methemoglobin concentration of 20% and asymptomatic patients at 30%; consider treatment at 10% to 30% when anemia, cardiopulmonary disease, carbon monoxide poisoning, or other impaired oxygen delivery is present. [21]
- Do not administer methylene blue to patients with G6PD deficiency because it may be ineffective and can precipitate severe hemolysis; discontinue it and pursue alternatives if severe hemolysis occurs. [1][16]
- After dapsone or aryl-amine/sulfa exposures, monitor serial methemoglobin by co-oximetry through resolution because levels may rebound after an initial methylene blue response. [1]

## When to suspect methemoglobinemia and what to do first

Treat clinically important oxygen-delivery failure while confirming the dyshemoglobinemia.

Suspect methemoglobinemia when cyanosis, dyspnea, neurologic symptoms, tachycardia, or low SpO2 is out of proportion to cardiopulmonary examination findings, particularly when hypoxemia appears refractory to supplemental oxygen. Dark or chocolate-brown blood and a normal PaO2 despite low pulse oximetry strengthen the diagnosis; neither finding replaces co-oximetry. [19][23]

Immediately stop the suspected oxidant medication or exposure, administer supplemental oxygen, and assess airway, ventilation, hemodynamics, mental status, ECG, hemoglobin concentration, and acid-base status. The clinical danger is functional anemia: ferric hemoglobin cannot bind oxygen, reducing effective oxygen-carrying capacity despite a measured total hemoglobin that may appear acceptable. [7][8][19]

Escalate urgency when there is altered mental status, hemodynamic instability, significant anemia, cardiac or pulmonary compromise, concomitant carbon monoxide poisoning, or rapidly rising methemoglobin. These conditions reduce oxygen-delivery reserve and justify treatment at lower methemoglobin concentrations than in otherwise healthy patients. [21]
- Ask specifically about dapsone, topical or local anesthetics, nitrates/nitrites, nitroglycerin, nitroprusside, nitric oxide, sulfonamides, nitrofurantoin, rasburicase, primaquine, chloroquine, phenazopyridine, aniline dyes, and oxidant industrial or ingestion exposures. [3][4][19]
- Recognize high-risk hosts: infants younger than 6 months, G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiopulmonary disease, and concurrent oxidant exposure. [3][4]
- After local anesthetic exposure, symptoms can occur immediately or be delayed for several hours; do not dismiss an initially normal examination if cyanosis or abnormal blood color develops after discharge-level observation. [3][4]

*Clinical pattern that should prompt immediate blood-gas co-oximetry. [7][19][23]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Cyanosis with low SpO2 and no major cardiac or pulmonary explanation | Dyshemoglobinemia is a key alternative to cardiopulmonary hypoxemia. [19][23] | Obtain venous or arterial blood gas with co-oximetry. [7][23] |
| Low SpO2 with normal PaO2 | Supports impaired hemoglobin oxygen carriage rather than impaired dissolved oxygen tension. [23] | Quantify methemoglobin by co-oximetry and review oxidant exposures. [7][12] |
| Chocolate-brown blood | Characteristic visual clue but not a quantitative test. [19][23] | Confirm with co-oximetry; begin exposure removal and oxygen support. [7][19] |
| Recent dapsone, benzocaine, lidocaine, prilocaine, nitrate/nitrite, or rasburicase exposure | Acquired oxidant methemoglobinemia is likely until proved otherwise. [3][4][16][19] | Stop the agent, assess for hemolysis when relevant, and obtain serial co-oximetry. [1][16] |

## Confirm with co-oximetry and interpret the saturation gap correctly

Co-oximetry establishes the diagnosis and guides treatment intensity.

Obtain co-oximetry on an arterial or venous blood gas in every patient with a credible clinical syndrome. Co-oximetry spectrophotometrically measures hemoglobin derivatives, including oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin, and methemoglobin, and is the preferred confirmatory test. [7][12][13][23]

Do not rely on calculated arterial oxygen saturation, routine pulse oximetry, or PaO2 to exclude disease. A saturation gap—difference between SpO2 and co-oximetry-derived SaO2—greater than 5% suggests an abnormal hemoglobin species, including methemoglobin, carboxyhemoglobin, or sulfhemoglobin. [13]

Interpret the methemoglobin percentage in clinical context rather than as an isolated antidote trigger. Acute acquired disease is generally less well tolerated than congenital disease because the rate of rise matters; congenital patients may have baseline concentrations of 20% to 40% with chronic cyanosis and relatively limited symptoms. [7][21]
- At methemoglobin concentrations above 20%, early symptoms may include headache, lightheadedness, fatigue, dyspnea, lethargy, tachycardia, and pallor. [7]
- Concentrations above 70% are potentially lethal, although individual tolerance varies with acuity and oxygen-delivery reserve. [7][21]
- Obtain a CBC when anemia is possible; methemoglobinemia functions as anemia, and a lower baseline hemoglobin reduces the total amount of functional hemoglobin at any given methemoglobin percentage. [7][8]

*Treatment-relevant interpretation of methemoglobin results in acquired disease. [21]*

| Clinical setting | Methemoglobin result | Decision |
| --- | --- | --- |
| Symptomatic acquired methemoglobinemia | 20% or higher. [21] | Give antidotal treatment after stopping the oxidant exposure and providing oxygen support. [21] |
| Asymptomatic acquired methemoglobinemia | 30% or higher. [21] | Treat and monitor with serial co-oximetry. [21] |
| Symptoms or impaired oxygen delivery from anemia, cardiac disease, lung disease, or carbon monoxide poisoning | 10% to 30%. [21] | Use a lower treatment threshold based on clinical severity and oxygen-delivery risk. [21] |
| Chronic hereditary methemoglobinemia | Higher concentrations may be tolerated than in acute acquired disease. [7][21] | Avoid applying acquired-disease thresholds without considering baseline status and symptoms. [21] |

## Distinguish acquired oxidant exposure from hereditary methemoglobinemia

The exposure timeline determines acute management and the subsequent diagnostic pathway.

Classify most new presentations as acquired when cyanosis begins recently after a medication, toxin, or environmental exposure. High-yield exposures include dapsone; benzocaine and other local anesthetics; nitrates and nitrites; nitroprusside and nitric oxide; sulfonamides; nitrofurantoin; antimalarials; rasburicase; and aniline dyes. [3][4][16][19][21]

Pursue hereditary evaluation after acquired triggers have been excluded or when cyanosis is longstanding, began in infancy, recurs without exposure, or occurs in relatives. Family history of dusky skin or blue sclera and consanguinity favor congenital disease; cardiac and pulmonary right-to-left shunting remain competing causes of central cyanosis that require independent evaluation. [18][21][24]

Measure cytochrome b5 reductase activity to distinguish hereditary CYB5R3 deficiency from acquired disease; it is the reference test for this branch point. Confirm congenital disease with molecular testing, which can identify CYB5R3-related disease and globin-gene variants causing HbM disease. Hemoglobin electrophoresis can help identify HbM variants. [18][21][24]

Before rasburicase, obtain G6PD testing because G6PD-deficient patients are at risk for both hemolysis and methemoglobinemia. If methemoglobinemia follows rasburicase, monitor for delayed hemolysis; in one reported pattern, hemolysis developed more than 30 hours after methemoglobinemia. [16]
- CYB5R activity less than 20% of normal supports congenital CYB5R3 deficiency. [24]
- HbM disease is associated with globin-gene variants and is inherited differently from autosomal recessive CYB5R3 deficiency; molecular testing clarifies the diagnosis when the phenotype is persistent. [22][24]
- Patients with known hereditary or acquired methemoglobinemia should avoid precipitating oxidant factors, including before surgery or during pregnancy planning. [18]

*Etiologic patterns and the next diagnostic action. [18][21][24]*

| Pattern | Most likely branch | Tests or actions that change management |
| --- | --- | --- |
| Abrupt cyanosis after a new drug, anesthetic, nitrate/nitrite, or toxin | Acquired oxidant methemoglobinemia. [3][4][19][21] | Stop exposure; quantify methemoglobin with co-oximetry; treat according to symptoms and concentration. [7][21] |
| Lifelong cyanosis, family history, blue sclera, or consanguinity | Hereditary methemoglobinemia. [18][21][24] | Measure CYB5R activity and obtain molecular testing; consider hemoglobin electrophoresis for HbM. [18][24] |
| Rasburicase exposure with methemoglobinemia or hemolysis | Oxidant event in possible G6PD deficiency. [16] | Check G6PD status and avoid methylene blue when deficiency is present or strongly suspected. [1][16] |
| Persistent cyanosis with no elevated methemoglobin | Alternative dyshemoglobinemia or cardiopulmonary disease. | Evaluate carboxyhemoglobin and sulfhemoglobin on co-oximetry when available; reassess for cardiac or pulmonary shunt disease. [13][21] |

## Treat acquired methemoglobinemia without causing hemolysis

Choose methylene blue by clinical severity and avoid it when its redox mechanism is unsafe.

For acquired methemoglobinemia meeting treatment thresholds, give intravenous methylene blue as first-line antidotal therapy unless contraindicated. Treatment is indicated at 20% methemoglobin in symptomatic patients and at 30% in asymptomatic patients; use lower thresholds in patients with reduced oxygen-delivery reserve. [13][21]

Do not give methylene blue to patients with G6PD deficiency. FDA labeling identifies G6PD deficiency as a contraindication because treatment can cause severe hemolysis and severe anemia; methylene blue may also be ineffective because its reduction to the active form depends on adequate reducing capacity. [1][16]

Avoid excessive cumulative methylene blue exposure. Doses greater than 7 mg/kg can themselves act as an oxidant and induce or worsen methemoglobinemia in susceptible patients. If severe hemolysis occurs, discontinue methylene blue and pursue alternative management. [1][7][14]

Use serial co-oximetry to document response and identify rebound. Rebound or incomplete resolution is specifically described after aryl-amine exposures such as aniline and sulfa drugs such as dapsone; continue monitoring through clinical and laboratory resolution rather than relying on transient improvement in cyanosis. [1]
- In G6PD deficiency or when methylene blue cannot be used, ascorbic acid is a slower direct reducer of methemoglobin and has been used in hereditary disease and in selected nonsevere presentations. [6][13][15]
- Consider exchange transfusion or hyperbaric oxygen as rescue options when the patient does not improve or methylene blue is contraindicated or cannot be used. [2][15]
- For dapsone-associated disease, do not assume a single response ends the episode; repeat methemoglobin measurements because rebound may occur. [1]

### Medication safety and exposure prevention

When a local anesthetic is necessary in a patient at increased risk—G6PD deficiency, congenital methemoglobinemia, infant age under 6 months, cardiopulmonary compromise, or concurrent oxidant drug exposure—use close clinical monitoring for cyanosis and abnormal blood color. [3][4]

After liposomal bupivacaine administration, avoid additional local anesthetics for 96 hours because concurrent local anesthetic exposure can increase methemoglobinemia risk. [4]

*Treatment selection and monitoring for acquired methemoglobinemia. [1][13][15][16][21]*

| Scenario | Action | Monitoring or escalation |
| --- | --- | --- |
| Symptomatic patient with methemoglobin 20% or higher | Stop oxidant exposure, provide oxygen support, and use intravenous methylene blue unless contraindicated. [13][21] | Repeat co-oximetry to document decline and clinical response. [1] |
| Asymptomatic patient with methemoglobin 30% or higher | Treat with methylene blue unless contraindicated. [21] | Follow serial methemoglobin until resolution. [1] |
| G6PD deficiency or strong suspicion of deficiency | Avoid methylene blue because of severe hemolysis risk and potential lack of efficacy. [1][16] | Use oxygen support; consider ascorbic acid and rescue exchange transfusion or hyperbaric oxygen when clinically necessary. [6][13][15] |
| Dapsone, aniline, or sulfa-associated disease | Remove exposure and treat by severity threshold. [1][21] | Monitor for rebound after initial response. [1] |
| No improvement or methylene blue cannot be used | Escalate to exchange transfusion or hyperbaric oxygen as second-line rescue therapy. [2][15] | Continue serial co-oximetry and organ-supportive care. [1][15] |

## Long-term management of hereditary and recurrent methemoglobinemia

Document the mechanism, establish a baseline, and prevent repeat oxidant injury.

After stabilization, patients with persistent elevation or a history consistent with congenital disease should have CYB5R activity measurement and molecular confirmation when available. This distinguishes CYB5R3 deficiency from HbM disease and provides the basis for counseling about inheritance, baseline cyanosis, and oxidant avoidance. [18][21][24]

Do not treat chronic cyanosis solely to normalize a laboratory value. Patients with congenital methemoglobinemia can tolerate higher baseline methemoglobin concentrations than patients with acute acquired disease; treatment decisions should instead incorporate symptoms, baseline concentration, and comorbid conditions that impair oxygen delivery. [7][21]

Oral methylene blue has been used as maintenance therapy in congenital disease, while oral ascorbic acid reduces methemoglobin slowly and has been used in hereditary disease. Long-term pharmacologic decisions require individualized hematology input because the available evidence is largely based on reports and small series. [6][13][20]
- Record confirmed G6PD deficiency prominently because methylene blue is contraindicated and oxidant drugs may cause hemolysis and methemoglobinemia. [1][16]
- Before procedures, review exposure to topical anesthetics and other oxidant drugs; patients with congenital disease or G6PD deficiency warrant heightened monitoring if local anesthetics are unavoidable. [3][4][18]
- Advise patients with a confirmed hereditary diagnosis to avoid known precipitating oxidants and to disclose the diagnosis during emergency care, surgery, and pregnancy-related care. [18]

*Follow-up priorities after an episode of methemoglobinemia. [1][18][21][24]*

| Clinical situation | Follow-up action | Purpose |
| --- | --- | --- |
| Single clear acquired exposure with normalization | Document culprit drug or toxin and avoid re-exposure. [1][19] | Prevents recurrent oxidant injury. |
| Persistent or recurrent cyanosis without a clear exposure | Measure CYB5R activity; obtain molecular testing and consider hemoglobin electrophoresis. [18][24] | Identifies CYB5R3 deficiency or HbM disease. |
| Rasburicase-associated event | Confirm G6PD status and monitor for hemolysis after the methemoglobinemia episode. [16] | Guides future drug avoidance and detects delayed hemolytic complications. [16] |
| Known hereditary disease | Establish baseline symptoms and methemoglobin level; review oxidant avoidance before surgery or pregnancy. [18][21] | Avoids unnecessary acute-style treatment and reduces preventable exacerbations. [18] |

## References
1. [PDF] Table of Pharmacogenomic Biomarkers in Drug Labeling - FDA — www.fda.gov — https://www.fda.gov/media/122407/download
2. 4169829 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201444s019lbl.pdf
3. [PDF] 209511Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/209511Orig1s000Lbl.pdf
4. [PDF] CENTER FOR DRUG EVALUATION AND RESEARCH — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/22496Orig1s037.pdf
5. An Update to the American Heart Association Guidelines for ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001161
6. A rare cause of cyanosis: Congenital methemoglobinemia - Guedri - 2021 - Clinical Case Reports - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.4422
7. Methemoglobinemia: When to Suspect and How to Treat : Current Medical Issues — journals.lww.com — https://journals.lww.com/cmii/fulltext/2019/17040/methemoglobinemia__when_to_suspect_and_how_to.7.aspx
8. Acquired methemoglobinemia: A systematic review of reported cases - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1473050221002998
9. Methemoglobinemia - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/methemoglobinemia
10. Acquired methemoglobinemia induced by dapsone in... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2025/07250/acquired_methemoglobinemia_induced_by_dapsone_in_a.103.aspx
11. A Case of Rapid Methemoglobinemia Following Topical Anesthetics — academic.oup.com — https://academic.oup.com/ajrccm/article/211/Supplement_1/A2586/8334794
12. Laboratory Assessment of Oxygenation in Methemoglobinemia — academic.oup.com — https://academic.oup.com/clinchem/article-abstract/51/2/434/5629640
13. Successful management of methemoglobinemia with oral... : MRIMS Journal of Health Sciences — journals.lww.com — https://journals.lww.com/mjhs/fulltext/2025/10000/successful_management_of_methemoglobinemia_with.15.aspx
14. Methylene blue-induced Hemolysis in a patient with lidocaine-induced Methemoglobinemia: a case report | Oxford Medical Case Reports | Oxford Academic — academic.oup.com — https://academic.oup.com/omcr/article/2025/12/omaf264/8404891
15. Acute methemoglobinemia due to ingestion of MAHIA... : Annals of African Medicine — journals.lww.com — https://journals.lww.com/aoam/fulltext/2016/15040/acute_methemoglobinemia_due_to_ingestion_of_mahia.9.aspx
16. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23182
17. Pulse Fiction: The Sp O 2 –Sa O 2 Gap in Methemoglobinemia — academic.oup.com — https://academic.oup.com/annalsats/article/21/11/1610/8380734
18. Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8598222
19. Methemoglobinemia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69535b8d003dc56acd1231a8
20. Congenital Methemoglobinemia in a 33-Year-Old Patient: A Case Report on a Rare Presentation and a Review of the Literature - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10082972
21. Recommendations for diagnosis and treatment of methemoglobinemia - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9291883
22. Recommendations for diagnosis and treatment of methemoglobinemia. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/34467556
23. Methemoglobinemia: from diagnosis to treatment - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/19082413
24. A blue blood toddler– a case report of methemoglobinemia and literature review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11846283

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.